Lluís Masana1, Eudald Correig2, Cèlia Rodríguez-Borjabad1, Eva Anoro3, Juan Antonio Arroyo4, Carlos Jericó5, Angels Pedragosa6, Marcel la Miret7, Silvia Näf8, Anna Pardo9, Verónica Perea10, Rosa Pérez-Bernalte11, Núria Plana1, Rafael Ramírez-Montesinos12, Meritxell Royuela13, Cristina Soler14, Maria Urquizu-Padilla15, Alberto Zamora16, Juan Pedro-Botet17. 1. CIBERDEM, Universitat Rovira i Virgili, LIPIDCAS, University Hospital Sant Joan IISPV, Reus, Spain. 2. Universitat Rovira i Virgili, Statistics Department, Institut Investigació Sanitaria Pere Virgili, Reus, Spain. 3. LIPIDCAS, Pius Hospital Valls, Valls, Spain. 4. Lipid Unit, University Hospital Santa Creu i Sant Pau, Barcelona Autonomous University, Barcelona, Spain. 5. Lipid Unit, Hospital Moises Broggi, Consorci Sanitari Integral, Sant Joan Despí, Spain. 6. Lipid Unit, Consorci Sanitari Terrassa, Spain. 7. LIPIDCAS, Endocrinology Department, Hospital Verge de la Cinta, Tortosa, Spain. 8. LIPIDCAS, Endocrinology Department, University Hospital Joan XXIII, IISPV, CIBERDEM, Universitat Rovira i Virgili, Tarragona, Spain. 9. Internal Medicine Department, Hospital Delfos, Barcelona, Spain. 10. Lipid Unit, Hospital Mutua Terrasa, Barcelona, Spain. 11. LIPIDCAS, Hospital del Vendrell, El Vendrell, Spain. 12. LIPIDCAS, Hospital Sant Pau i Santa Tecla, Tarragona, Spain. 13. Lipid Unit, ALTHAIA, Xarxa Assistencial Universitària de Manresa, Spain. 14. Lipid Unit, Hospital Santa Caterina, Girona, Spain. 15. Lipid Unit, University Hospital Vall d'Hebron, Barcelona Autonomous University, Barcelona, Spain. 16. Lipid Unit, Corporació de Salut del Maresme i la Selva, Hospital de Blanes, Spain. 17. Lipid Unit, University Hospital del Mar, Barcelona Autonomous University, Barcelona, Spain.
Abstract
AIM: Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-hospital mortality. METHODS AND RESULTS: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk. Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients [1234 men, 923 women; age: 67 y/o (IQR 54-78)] admitted to the hospital were retrieved from the clinical records in anonymized manner. Three hundred and fifty-three deaths occurred. Five hundred and eighty-one patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on ST than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: P = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared with the GM non-statin group (17.4%; P = 0.045). The Cox model applied to the CSH function [HR = 0.58(CI: 0.39-0.89); P = 0.01] and the competing-risks FG model [HR = 0.60 (CI: 0.39-0.92); P = 0.02] suggest that statins are associated with reduced COVID-19-related mortality. CONCLUSIONS: A lower SARS-CoV-2 infection-related mortality was observed in patients treated with ST prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19. Published on behalf of the European Society of Cardiology. All rights reserved.
AIM: Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-hospital mortality. METHODS AND RESULTS: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk. Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients [1234 men, 923 women; age: 67 y/o (IQR 54-78)] admitted to the hospital were retrieved from the clinical records in anonymized manner. Three hundred and fifty-three deaths occurred. Five hundred and eighty-one patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on ST than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: P = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared with the GM non-statin group (17.4%; P = 0.045). The Cox model applied to the CSH function [HR = 0.58(CI: 0.39-0.89); P = 0.01] and the competing-risks FG model [HR = 0.60 (CI: 0.39-0.92); P = 0.02] suggest that statins are associated with reduced COVID-19-related mortality. CONCLUSIONS: A lower SARS-CoV-2 infection-related mortality was observed in patients treated with ST prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Mariana Alves; Marília Andreia Fernandes; Gülistan Bahat; Athanase Benetos; Hugo Clemente; Tomasz Grodzicki; Manuel Martínez-Sellés; Francesco Mattace-Raso; Chakravarthi Rajkumar; Andrea Ungar; Nikos Werner; Timo E Strandberg Journal: Eur Geriatr Med Date: 2021-05-25 Impact factor: 1.710
Authors: Lluís Masana; Eudald Correig; Daiana Ibarretxe; Eva Anoro; Juan Antonio Arroyo; Carlos Jericó; Carolina Guerrero; Marcel la Miret; Silvia Näf; Anna Pardo; Verónica Perea; Rosa Pérez-Bernalte; Núria Plana; Rafael Ramírez-Montesinos; Meritxell Royuela; Cristina Soler; Maria Urquizu-Padilla; Alberto Zamora; Juan Pedro-Botet Journal: Sci Rep Date: 2021-03-30 Impact factor: 4.379
Authors: Zachary A Yetmar; Douglas W Challener; Imad M Tleyjeh; M Rizwan Sohail; James R Cerhan; Andrew D Badley; John C O'Horo Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-03-14
Authors: Geert Byttebier; Luc Belmans; Myriam Alexander; Bo E H Saxberg; Bart De Spiegeleer; Anton De Spiegeleer; Nick Devreker; Jens T Van Praet; Karolien Vanhove; Reinhilde Reybrouck; Evelien Wynendaele; David S Fedson Journal: Hum Vaccin Immunother Date: 2021-05-28 Impact factor: 3.452